<DOC>
	<DOCNO>NCT02208297</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy loteprednol etabonate ( LE ) ophthalmic gel , 0.38 % ( BID )</brief_summary>
	<brief_title>Loteprednol Etabonate Ophthalmic Gel Treatment Ocular Inflammation Pain Following Cataract Surgery</brief_title>
	<detailed_description>The objective study evaluate safety efficacy loteprednol etabonate ( LE ) ophthalmic gel , 0.38 % ( BID ) treatment inflammation pain follow cataract surgery .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Loteprednol Etabonate</mesh_term>
	<criteria>Visit 1 ( Screening Visit ) Be willing able comply treatment followup/study procedure . Be candidate routine , uncomplicated cataract surgery . Visit 3 ( Postoperative Day 1 ) Have undergone routine , uncomplicated cataract surgery ( phacoemulsification posterior chamber intraocular lens ( IOL ) implantation , combine surgery ) study eye . Have â‰¥ Grade 2 anterior chamber ( AC ) cell ( 615 cell ) study eye . Have severe/serious ocular condition history/presence chronic generalize systemic disease Investigator feel might increase risk subject confound result ( ) study . Have know hypersensitivity contraindication study drug ( ) component .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>